Paclitaxel, topotecan, and carboplatin in metastatic endometrial cancinoma: a Hellenic Co-operative Oncology Group (HeCOG) study. (Q40413780)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18644619%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

title

Paclitaxel, topotecan, and carboplatin in metastatic endometrial cancinoma: a Hellenic Co-operative Oncology Group (HeCOG) study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18644619%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18644619%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

H P Kalofonos

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18644619%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Athanasios Dimopoulos

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18644619%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

3

Dimitrios Bafaloukos

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18644619%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

6

Dimitrios Pectasides

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18644619%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Gerassimos Aravantinos

7

object named as

Gerassimos Aravantinos

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18644619%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

8

Aristotelis Bamias

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18644619%20AND%20SRC:MED&resulttype=core&format=json

Hellenic Co-operative Oncology Group

11 January 2020

10

object named as

Hellenic Co-operative Oncology Group

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18644619%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

author name string

Christos A Papadimitriou

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18644619%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

George Fountzilas

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18644619%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

language of work or name

English

0 references

publication date

21 July 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18644619%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18644619%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

volume

111

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18644619%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18644619%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

page(s)

27-34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18644619%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

cites work

Endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

Cancer of the endometrium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

Systemic therapy in metastatic or recurrent endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

Treatment of advanced or recurrent endometrial carcinoma with single-agent carboplatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

inferred from DOI database lookup

7 January 2021

based on heuristic

Current Status of Taxane and Platinum-Based Chemotherapy in Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

Effects of CPT-11 in combination with other anti-cancer agents in culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

Inhibition of cis-diamminedichloroplatinum (II)-induced DNA interstrand cross-link removal by 7-ethyl-10-hydroxy-camptothecin in HST-1 human squamous-carcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group Study E3E93.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

Paclitaxel and Cisplatin in Advanced or Recurrent Carcinoma of the Endometrium: Long-Term Results of a Phase II Multicenter Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

Reporting results of cancer treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

The calculation of received dose intensity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

Nonparametric Estimation from Incomplete Observations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

Carboplatin and paclitaxel in advanced or metastatic endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

Phase I dose escalation study of topotecan combined with alternating schedules of paclitaxel and carboplatin in advanced solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

Phase I Trial of Carboplatin and Paclitaxel With Escalating Doses of Oral Topotecan in Patients With Solid Tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

Phase II Trial of Paclitaxel, Carboplatin, and Topotecan with G-CSF Support in Previously Untreated Patients with Extensive Stage Small Cell Lung Cancer: Southwest Oncology Group 9914

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

Emerging role of topotecan in front-line treatment of carcinoma of the ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

Update on the treatment of cervical and uterine carcinoma: focus on topotecan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.001

10.1016/J.YGYNO.2008.06.001

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18644619%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

1 reference